WallStreetZenWallStreetZen

NASDAQ: AKTS
Aktis Oncology Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for AKTS

Based on 2 analysts offering 12 month price targets for Aktis Oncology Inc

Min Forecast
$30.00+45.77%
Avg Forecast
$31.50+53.06%
Max Forecast
$33.00+60.35%

Should I buy or sell AKTS stock?

Based on 2 analysts offering ratings for Aktis Oncology Inc.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although AKTS's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates AKTS as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their AKTS stock forecasts and price targets.

AKTS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-31
lockedlocked$00.00+00.00%2026-02-03
lockedlocked$00.00+00.00%2026-02-03

1 of 1

Forecast return on equity

Is AKTS forecast to generate an efficient return?

Company
N/A
Industry
85.8%
Market
169.74%

Forecast return on assets

Is AKTS forecast to generate an efficient return on assets?

Company
N/A
Industry
29.42%

AKTS earnings per share forecast

What is AKTS's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
-$1.71
Avg 2 year Forecast
-$2.35
Avg 3 year Forecast
-$3.66

AKTS revenue forecast

What is AKTS's revenue in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$20.4M
Avg 2 year Forecast
$18.2M
Avg 3 year Forecast
$2.0M

AKTS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AKTS$19.12$31.50+64.75%Strong Buy
MNKD$3.31$8.13+145.47%Buy
IVA$5.21$13.75+163.92%Strong Buy
SVRA$5.06$9.50+87.75%Strong Buy
LXRX$2.23$4.55+104.04%Strong Buy
View Top Biotech Stocks

Aktis Oncology Stock Forecast FAQ

Is Aktis Oncology Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: AKTS) stock is to Strong Buy AKTS stock.

Out of 2 analysts, 1 (50%) are recommending AKTS as a Strong Buy, 1 (50%) are recommending AKTS as a Buy, 0 (0%) are recommending AKTS as a Hold, 0 (0%) are recommending AKTS as a Sell, and 0 (0%) are recommending AKTS as a Strong Sell.

If you're new to stock investing, here's how to buy Aktis Oncology stock.

What is AKTS's earnings growth forecast for 2026-2028?

(NASDAQ: AKTS) Aktis Oncology's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.38%.

Aktis Oncology's earnings in 2026 is N/A.On average, 8 Wall Street analysts forecast AKTS's earnings for 2026 to be -$91,380,642, with the lowest AKTS earnings forecast at -$108,859,973, and the highest AKTS earnings forecast at -$67,850,567. On average, 8 Wall Street analysts forecast AKTS's earnings for 2027 to be -$125,725,152, with the lowest AKTS earnings forecast at -$160,673,134, and the highest AKTS earnings forecast at -$84,112,273.

In 2028, AKTS is forecast to generate -$195,284,667 in earnings, with the lowest earnings forecast at -$192,075,049 and the highest earnings forecast at -$196,261,971.

What is AKTS's revenue growth forecast for 2026-2028?

(NASDAQ: AKTS) Aktis Oncology's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.05%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.75%.

Aktis Oncology's revenue in 2026 is N/A.On average, 8 Wall Street analysts forecast AKTS's revenue for 2026 to be $1,086,837,381, with the lowest AKTS revenue forecast at $366,355,679, and the highest AKTS revenue forecast at $2,984,890,909. On average, 8 Wall Street analysts forecast AKTS's revenue for 2027 to be $971,002,764, with the lowest AKTS revenue forecast at $314,019,154, and the highest AKTS revenue forecast at $2,242,993,956.

In 2028, AKTS is forecast to generate $108,945,421 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $336,449,093.

What is AKTS's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: AKTS) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 29.42%.

What is AKTS's Price Target?

According to 2 Wall Street analysts that have issued a 1 year AKTS price target, the average AKTS price target is $31.50, with the highest AKTS stock price forecast at $33.00 and the lowest AKTS stock price forecast at $30.00.

On average, Wall Street analysts predict that Aktis Oncology's share price could reach $31.50 by Mar 31, 2027. The average Aktis Oncology stock price prediction forecasts a potential upside of 64.75% from the current AKTS share price of $19.12.

What is AKTS's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: AKTS) Aktis Oncology's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that AKTS's EPS will be -$1.71 for 2026, with the lowest EPS forecast at -$2.04, and the highest EPS forecast at -$1.27. On average, analysts forecast that AKTS's EPS will be -$2.35 for 2027, with the lowest EPS forecast at -$3.01, and the highest EPS forecast at -$1.58. In 2028, AKTS's EPS is forecast to hit -$3.66 (min: -$3.60, max: -$3.68).

What is AKTS's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: AKTS) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.